Our Products | Takeda UK

Shire is now part of Takeda.

The current Takeda UK portfolio comprises of the following medicines.

To download a patient information leaflet (PIL) and a summary of product characteristics (SmPC) for each medicine, simply follow the links within the expandable table below.

If you are a member of the public requiring advice or information on your own medical condition or treatments listed below please contact your own doctor or NHS Choices in the first instance.

BUCCOLAM 2.5 mg, 5 mg, 7.5 mg and 10 mg Oromucosal Solution Alert

Please click here for for information and guidance for healthcare professionals regarding the Buccolam tip-cap issue and correct use of the product.

Actos® - pioglitazone hydrochloride

Name	Summary of Product Characteristics	Patient Information Leaflet
Actos 15 mg, 30 mg, 45 mg tablets	Summary of product characteristics SmPC	Patient Information leaflet PIL

Adcetris®▼ - brentuximab vedotin

Name	Summary of Product Characteristics	Patient Information Leaflet
Adcetris 50 mg powder for concentrate for solution for infusion	Summary of product characteristics SmPC	Patient Information leaflet PIL

Advate® - octocog alfa

Name	Summary of Product Characteristics	Patient Information Leaflet
Advate 250 IU, 500 IU, 1000 IU, 1500 IU, 2000 IU and 3000 IU powder and solvent for solution for injection 2 ml water – Baxject II	Summary of product characteristics SmPC	Patient Information leaflet PIL
Advate 250 IU, 500 IU, 1000 IU, 1500 IU, 2000 IU and 3000 IU powder and solvent for solution for injection 5 ml water – Baxject II	Summary of product characteristics SmPC	Patient Information leaflet PIL

Adynovi®▼ - rurioctocog alfa pegol

Name	Summary of Product Characteristics	Patient Information Leaflet
Adynovi 1000 IU powder and solvent for solution for injection 2 ml solvent	Summary of product characteristics SmPC	Patient Information leaflet PIL
Adynovi 1000 IU powder and solvent for solution for injection 5 ml solvent	Summary of product characteristics SmPC	Patient Information leaflet PIL
Adynovi 2000 IU powder and solvent for solution for injection 5 ml solvent	Summary of product characteristics SmPC	Patient Information leaflet PIL
Adynovi 250 IU powder and solvent for solution for injection 2 ml solvent	Summary of product characteristics SmPC	Patient Information leaflet PIL
Adynovi 250 IU powder and solvent for solution for injection 5 ml solvent	Summary of product characteristics SmPC	Patient Information leaflet PIL
Adynovi 500 IU powder and solvent for solution for injection 2 ml solvent	Summary of product characteristics SmPC	Patient Information leaflet PIL
Adynovi 500 IU powder and solvent for solution for injection 5 ml solvent	Summary of product characteristics SmPC	Patient Information leaflet PIL

Alofisel®▼ - darvadstrocel

Name	Summary of Product Characteristics	Patient Information Leaflet	Risk Materials
Alofisel 5 million cells/mL suspension for injection	Summary of product characteristics SmPC	Patient Information leaflet PIL	Risk materials

Alunbrig®▼ - brigatinib

Name	Summary of Product Characteristics	Patient Information Leaflet	Risk Materials
Alunbrig 30 mg, 90 mg, 180 mg film-coated tablets	Summary of product characteristics SmPC	Patient Information leaflet PIL	Risk materials

Amias® - candesartan cilexetil

Name	Summary of Product Characteristics	Patient Information Leaflet
Amias 2 mg, 4 mg, 8 mg, 16 mg, 32 mg tablets	Summary of product characteristics SmPC	Patient Information leaflet PIL

Buccolam - midazolam hydrochloride

Name	Summary of Product Characteristics	Patient Information Leaflet	Risk materials
Buccolam 2.5 mg oromucosal solution	Summary of product characteristics SmPC	Patient Information Leaflet PIL	Risk materials
Buccolam 5 mg oromucosal solution	Summary of product characteristics SmPC	Patient Information leaflet PIL	Risk materials
Buccolam 7.5 mg oromucosal solution	Summary of product characteristics SmPC	Patient Information leaflet PIL	Risk materials
Buccolam 10 mg oromucosal solution	Summary of product characteristics SmPC	Patient Information leaflet PIL	Risk materials

Calcichew® Portfolio - calcium carbonate +/- cholecalciferol

Name	Summary of Product Characteristics	Patient Information Leaflet
Calcichew 500 mg chewable tablets	Summary of product characteristics SmPC	Patient Information leaflet PIL
Calcichew D₃ chewable tablets	Summary of product characteristics SmPC	Patient Information leaflet PIL
Calcichew Forte chewable tablets	Summary of product characteristics SmPC	Patient Information leaflet PIL
Calcichew D₃ 1000 mg/800 IU once daily chewable tablets	Summary of product characteristics SmPC	Patient Information leaflet PIL
Calcichew D₃ Forte chewable tablets	Summary of product characteristics SmPC	Patient Information leaflet PIL

Ceprotin - protein c

Name	Summary of Product Characteristics	Patient Information Leaflet
Ceprotin 1000 IU powder and solvent for solution for injection	Summary of product characteristics SmPC	Patient Information leaflet PIL
Ceprotin 500 IU powder and solvent for solution for injection	Summary of product characteristics SmPC	Patient Information leaflet PIL

Cinryze®▼ - C1 inhibitor [human]

Name	Summary of Product Characteristics	Patient Information Leaflet	Risk materials
Cinryze 500 IU powder and solvent for solution for injection	Summary of product characteristics SmPC	Patient Information leaflet PIL	Risk materials

Competact® - pioglitazone hydrochloride/metformin hydrochloride

Name	Summary of Product Characteristics	Patient Information Leaflet
Competact 15 mg/850 mg film-coated tablets	Summary of product characteristics SmPC	Patient Information leaflet PIL

Condyline® - podophyllotoxin

Name	Summary of Product Characteristics	Patient Information Leaflet
Condyline 0.5% w/v Cutaneous Solution	Summary of product characteristics SmPC	Patient Information leaflet PIL

Cuvitru®▼ - human normal immunoglobulin

Name	Summary of Product Characteristics	Patient Information Leaflet
Cuvitru 200 mg/ml solution for subcutaneous injection	Summary of product characteristics SmPC	Patient Information leaflet PIL

Edarbi® - azilsartan medoxomil potassium

Name	Summary of Product Characteristics	Patient Information Leaflet
Edarbi 20 mg, 40 mg, 80 mg tablets	Summary of product characteristics SmPC	Patient Information leaflet PIL

Elaprase®▼ - idursulfase

Name	Summary of Product Characteristics	Patient Information Leaflet
Elaprase 2 mg/ml concentrate for solution for infusion	Summary of product characteristics SmPC	Patient Information leaflet PIL

Elvanse® - lisdexamfetamine dimesylate

Name	Summary of Product Characteristics	Patient Information Leaflet
Elvanse 20 mg hard capsules	Summary of product characteristics SmPC	Patient Information leaflet PIL
Elvanse 30 mg hard capsules	Summary of product characteristics SmPC	Patient Information leaflet PIL
Elvanse 40 mg hard capsules	Summary of product characteristics SmPC	Patient Information leaflet PIL
Elvanse 50 mg hard capsules	Summary of product characteristics SmPC	Patient Information leaflet PIL
Elvanse 60 mg hard capsules	Summary of product characteristics SmPC	Patient Information leaflet PIL
Elvanse 70 mg hard capsules	Summary of product characteristics SmPC	Patient Information leaflet PIL
Elvanse Adult 30 mg hard capsules ▼	Summary of product characteristics SmPC	Patient Information leaflet PIL
Elvanse Adult 50 mg hard capsules ▼	Summary of product characteristics SmPC	Patient Information leaflet PIL
Elvanse Adult 70 mg hard capsules ▼	Summary of product characteristics SmPC	Patient Information leaflet PIL

Entyvio® - vedolizumab

Name	Summary of Product Characteristics	Patient Information Leaflet
Entyvio 300 mg powder for concentrate for solution for infusion	Summary of product characteristics SmPC	Patient Information leaflet PIL
Entyvio 108 mg solution for injection in pre-filled syringe	Summary of product characteristics SmPC	Patient Information leaflet PIL

Equasym® - methylphenidate hydrochloride

Name	Summary of Product Characteristics	Patient Information Leaflet
Equasym XL 10 mg modified-release capsules, hard	Summary of product characteristics SmPC	Patient Information leaflet PIL
Equasym XL 20 mg modified-release capsules, hard	Summary of product characteristics SmPC	Patient Information leaflet PIL
Equasym XL 30 mg modified-release capsules, hard	Summary of product characteristics SmPC	Patient Information leaflet PIL

Feiba® - factor viii inhibitor bypassing fraction

Name	Summary of Product Characteristics	Patient Information Leaflet
FEIBA 25 U/ml powder and solvent for solution for infusion	Summary of product characteristics SmPC	Patient Information leaflet PIL
FEIBA 50 U/ml powder and solvent for solution for infusion	Summary of product characteristics SmPC	Patient Information leaflet PIL

Firazyr® - icatibant acetate

Name	Summary of Product Characteristics	Patient Information Leaflet
Firazyr 30 mg solution for injection in pre-filled syringe	Summary of product characteristics SmPC	Patient Information leaflet PIL

Flexbumin - human albumin

Name	Summary of Product Characteristics	Patient Information Leaflet
Flexbumin 200 g/l solution for infusion	Summary of product characteristics SmPC	Patient Information leaflet PIL

Fosrenol - lanthanum carbonate hydrate

Name	Summary of Product Characteristics	Patient Information Leaflet
Fosrenol 500 mg chewable tablets	Summary of product characteristics SmPC	Patient Information leaflet PIL
Fosrenol 750 mg chewable tablets	Summary of product characteristics SmPC	Patient Information leaflet PIL
Fosrenol 1000 mg chewable tablets	Summary of product characteristics SmPC	Patient Information leaflet PIL
Fosrenol 750 mg oral powder	Summary of product characteristics SmPC	Patient Information leaflet PIL
Fosrenol 1000 mg oral powder	Summary of product characteristics SmPC	Patient Information leaflet PIL

Gammagard - human normal immunoglobulin

Name	Summary of Product Characteristics	Patient Information Leaflet
Gammagard S/D 5 g powder and solvent for solution for infusion	Summary of product characteristics SmPC	Patient Information leaflet PIL
Gammagard S/D 10 g powder and solvent for solution for infusion	Summary of product characteristics SmPC	Patient Information leaflet PIL

HyQvia®▼ - human normal immunoglobulin

Name	Summary of Product Characteristics	Patient Information Leaflet
HyQvia 100 mg/ml solution for infusion for subcutaneous use	Summary of product characteristics SmPC	Patient Information leaflet PIL

Instanyl® - fentanyl citrate

Name	Summary of Product Characteristics	Patient Information Leaflet	Risk Materials
Instanyl 50 mcg nasal spray, solution in single-dose container	Summary of product characteristics SmPC	Patient Information leaflet PIL	Risk materials
Instanyl 100 mcg nasal spray, solution in single-dose container	Summary of product characteristics SmPC	Patient Information leaflet PIL	Risk materials
Instanyl 200 mcg nasal spray, solution in single-dose container	Summary of product characteristics SmPC	Patient Information leaflet PIL	Risk materials

Intuniv®▼ - guanfacine hydrochloride

Name	Summary of Product Characteristics	Patient Information Leaflet
Intuniv® 1 mg prolonged-release tablets	Summary of product characteristics SmPC	Patient Information leaflet PIL
Intuniv® 2 mg prolonged-release tablets	Summary of product characteristics SmPC	Patient Information leaflet PIL
Intuniv® 3 mg prolonged-release tablets	Summary of product characteristics SmPC	Patient Information leaflet PIL
Intuniv® 4 mg prolonged-release tablets	Summary of product characteristics SmPC	Patient Information leaflet PIL

Kiovig® - human immunoglobulin

Name	Summary of Product Characteristics	Patient Information Leaflet
Kiovig 100 mg/ml solution for infusion	Summary of product characteristics SmPC	Patient Information leaflet PIL

Matrifen® - fentanyl

Name	Summary of Product Characteristics	Patient Information Leaflet	Risk Materials
Matrifen 12 micrograms/hour transdermal patch	Summary of product characteristics SmPC	Patient Information leaflet PIL	Risk materials
Matrifen 25 micrograms/hour transdermal patch	Summary of product characteristics SmPC	Patient Information leaflet PIL	Risk materials
Matrifen 50 micrograms/hour transdermal patch	Summary of product characteristics SmPC	Patient Information leaflet PIL	Risk materials
Matrifen 75 micrograms/hour transdermal patch	Summary of product characteristics SmPC	Patient Information leaflet PIL	Risk materials
Matrifen 100 micrograms/hour transdermal patch	Summary of product characteristics SmPC	Patient Information leaflet PIL	Risk materials

Mepact® - mifamurtide

Name	Summary of Product Characteristics	Patient Information Leaflet
Mepact 4 mg powder for suspension for infusion	Summary of product characteristics SmPC	Patient Information leaflet PIL

Mezavant - mesalazine

Name	Summary of Product Characteristics	Patient Information Leaflet
Mezavant XL 1200mg, gastro-resistant, prolonged release tablets.	Summary of product characteristics SmPC	Patient Information leaflet PIL

Natpar▼ - parathyroid hormone

Name	Summary of Product Characteristics	Patient Information Leaflet
Natpar 25 micrograms/dose powder and solvent for solution for injection	Summary of product characteristics SmPC	Patient Information leaflet PIL
Natpar 50 micrograms/dose powder and solvent for solution for injection	Summary of product characteristics SmPC	Patient Information leaflet PIL
Natpar 75 micrograms/dose powder and solvent for solution for injection	Summary of product characteristics SmPC	Patient Information leaflet PIL
Natpar 100 micrograms/dose powder and solvent for solution for injection	Summary of product characteristics SmPC	Patient Information leaflet PIL

Ninlaro®▼ - ixazomib citrate

Name	Summary of Product Characteristics	Patient Information Leaflet
Ninlaro 2.3 mg hard capsules	Summary of product characteristics SmPC	Patient Information leaflet PIL
Ninlaro 3 mg hard capsules	Summary of product characteristics SmPC	Patient Information leaflet PIL
Ninlaro 4 mg hard capsules	Summary of product characteristics SmPC	Patient Information leaflet PIL

Obizur®▼ - porcine factor VIII:c, antihaemophilic factor, susoctocog alfa

Name	Summary of Product Characteristics	Patient Information Leaflet
Obizur 500 U powder and solvent for solution for injection	Summary of product characteristics SmPC	Patient Information leaflet PIL

Plenadren® - hydrocortisone

Name	Summary of Product Characteristics	Patient Information Leaflet
Plenadren 5 mg modified-release tablets	Summary of product characteristics SmPC	Patient Information leaflet PIL
Plenadren 20 mg modified-release tablets	Summary of product characteristics SmPC	Patient Information leaflet PIL

Prostap® SR DCS and Prostap®3 DCS - leuprorelin acetate

Name	Summary of Product Characteristics	Patient Information Leaflet
Prostap 3 DCS 11.25 mg powder and solvent for prolonged-release suspension for injection in pre-filled syringe	Summary of product characteristics SmPC	Patient Information leaflet PIL
Prostap SR DCS 3.75 mg powder and solvent for prolonged-release suspension for injection in pre-filled syringe	Summary of product characteristics SmPC	Patient Information leaflet PIL

Prothromplex - human coagulation factor II, human coagulation factor VII, human coagulation factor IX, human coagulation factor X

Name	Summary of Product Characteristics	Patient Information Leaflet
Prothromplex Total 600 IU powder and solvent for solution for injection	Summary of product characteristics SmPC	Patient Information leaflet PIL

Protium® - pantoprazole

Name	Summary of Product Characteristics	Patient Information Leaflet
Protium 40 mg i.v. powder for solution for injection	Summary of product characteristics SmPC	Patient Information leaflet PIL
Pantoprazole 20 mg gastro-resistant tablets	Summary of product characteristics SmPC	Patient Information leaflet PIL
Pantoprazole 40 mg gastro-resistant tablets	Summary of product characteristics SmPC	Patient Information leaflet PIL

Reminyl - galantamine hydrobromide

Name	Summary of Product Characteristics	Patient Information Leaflet
Reminyl 4 mg/ml oral solution	Summary of product characteristics SmPC	Patient Information leaflet PIL
Reminyl XL 8 mg prolonged-release capsules, hard	Summary of product characteristics SmPC	Patient Information leaflet PIL
Reminyl XL 16 mg prolonged-release capsules, hard	Summary of product characteristics SmPC	Patient Information leaflet PIL
Reminyl XL 24 mg prolonged-release capsules, hard	Summary of product characteristics SmPC	Patient Information leaflet PIL

Replagal® - agalsidase alfa

Name	Summary of Product Characteristics	Patient Information Leaflet
Replagal 1 mg/ml concentrate for solution for infusion	Summary of product characteristics SmPC	Patient Information leaflet PIL

Resolor - prucalopride succinate

Name	Summary of Product Characteristics	Patient Information Leaflet
Resolor 1mg film-coated tablets	Summary of product characteristics SmPC	Patient Information leaflet PIL
Resolor 2mg film-coated tablets	Summary of product characteristics SmPC	Patient Information leaflet PIL

Revestive▼ - teduglutide

Name	Summary of Product Characteristics	Patient Information Leaflet
Revestive 1.25 mg powder and solvent for solution for injection	Summary of product characteristics SmPC	Patient Information leaflet PIL
Revestive 5 mg powder and solvent for solution for injection	Summary of product characteristics SmPC	Patient Information leaflet PIL

Rixubis® - nonacog gamma

Name	Summary of Product Characteristics	Patient Information Leaflet
Rixubis 250 IU powder and solvent for solution for injection	Summary of product characteristics SmPC	Patient Information leaflet PIL
Rixubis 500 IU powder and solvent for solution for injection	Summary of product characteristics SmPC	Patient Information leaflet PIL
Rixubis 1000 IU powder and solvent for solution for injection	Summary of product characteristics SmPC	Patient Information leaflet PIL
Rixubis 2000 IU powder and solvent for solution for injection	Summary of product characteristics SmPC	Patient Information leaflet PIL
Rixubis 3000 IU powder and solvent for solution for injection	Summary of product characteristics SmPC	Patient Information leaflet PIL

Subcuvia - human normal immunoglobulin

Name	Summary of Product Characteristics	Patient Information Leaflet
Subcuvia 160 g/l Solution for Injection	Summary of product characteristics SmPC	Patient Information leaflet PIL

TachoSil® - human fibrinogen, human thrombin

Name	Summary of Product Characteristics	Patient Information Leaflet
TachoSil sealant matrix	Summary of product characteristics SmPC	Patient Information leaflet PIL

Takhzyro▼ - lanadelumab

Name	Summary of Product Characteristics	Patient Information Leaflet
Takhzyro 300 mg solution for injection	Summary of product characteristics SmPC	Patient Information leaflet PIL

Veyvondi▼ - vonicog alfa

Name	Summary of Product Characteristics	Patient Information Leaflet
Veyvondi 1300 IU powder and solvent for solution for injection	Summary of product characteristics SmPC	Patient Information leaflet PIL
Veyvondi 650 IU powder and solvent for solution for injection	Summary of product characteristics SmPC	Patient Information leaflet PIL

Vipdomet® - alogliptin and metformin

Name	Summary of Product Characteristics	Patient Information Leaflet
Vipdomet 12.5 mg/1000 mg film-coated tablets	Summary of product characteristics SmPC	Patient Information leaflet PIL

Vipidia® - alogliptin benzoate

Name	Summary of Product Characteristics	Patient Information Leaflet
Vipidia 6.25 mg film-coated tablets	Summary of product characteristics SmPC	Patient Information leaflet PIL
Vipidia 12.5 mg film-coated tablets	Summary of product characteristics SmPC	Patient Information leaflet PIL
Vipidia 25 mg film-coated tablets	Summary of product characteristics SmPC	Patient Information leaflet PIL

Vpriv® - velaglucerase alfa

Name	Summary of Product Characteristics	Patient Information Leaflet
Vpriv 400 Units powder for solution for infusion	Summary of product characteristics SmPC	Patient Information leaflet PIL

Xagrid - anagrelide hydrochloride

Name	Summary of Product Characteristics	Patient Information Leaflet
Xagrid 0.5mg hard capsule	Summary of product characteristics SmPC	Patient Information leaflet PIL

The black triangle denotes this medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.

Adverse events should also be reported to Takeda UK Ltd:

Legacy-Takeda products - DSO-UK@takeda.com
Legacy-Shire products - drugsafety@shire.com

Medical Information

Our medical information service is intended to provide information on our products to Healthcare Professionals. For contact information, please view our Contact us page

UK/WBC/1707/0002d(4)

Date of Preparation: May 2020